Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986273 | 0.92 | PKM (0.42) | MAPTKMT2AL3MBTL1PKMAKR1C3 | |
| SCHEMBL4991400 | 0.90 | EPHX2 (0.41) | ALDH1A1AKR1C3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4989307 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTMKNK1KMT2AL3MBTL1 | |
| SCHEMBL4988076 | 0.89 | KMT2A (0.49) | ALDH1A1KMT2AL3MBTL1PKM | |
| SCHEMBL4988235 | 0.88 | MAPT (0.38) | ALDH1A1MAPTKMT2AAKR1C3CYP1A2 | |
| SCHEMBL4983020 | 0.85 | MEN1 (0.47) | ALDH1A1KMT2AL3MBTL1PKMAKR1C3 | |
| SCHEMBL4989326 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MAPTKMT2AL3MBTL1PKM | |
| SCHEMBL4986102 | 0.83 | PKM (0.44) | KMT2AL3MBTL1PKMPKLRAKR1C3 | |
| SCHEMBL4985355 | 0.81 | EPHX2 (0.37) | ALDH1A1KMT2AL3MBTL1GBA1AKR1C3 | |
| SCHEMBL4986044 | 0.81 | FAAH (0.39) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | ALDH1A1 3640/4885MAPT 4477/4885MKNK1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.